The aging mind: Vascular health in normal cognitive aging

Journal of the American Geriatrics Society

Volumn 58, Issue SUPPL. 2, 2010, Pages

  Warsch, Jessica R L ^a   Wright, Clinton B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

cerebrovascular disease; cognitive aging; risk factors

Indexed keywords

BIOLOGICAL MARKER;

AGED; AGING; ALZHEIMER DISEASE; BRAIN DAMAGE; CEREBROVASCULAR DISEASE; COGNITION; COGNITIVE DEFECT; COMORBIDITY; DEGENERATIVE DISEASE; DIAGNOSTIC IMAGING; HUMAN; INFLAMMATION; LIFE EXPECTANCY; LONGEVITY; NEURORADIOLOGY; PREVALENCE; REVIEW; RISK FACTOR; VASCULAR DISEASE;

AGED; AGING; BRAIN DISEASES; COGNITION; DISEASE PROGRESSION; HUMANS; PROGNOSIS; REFERENCE VALUES; RISK FACTORS; VASCULAR DISEASES;

EID: 77957367962     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2010.02983.x     Document Type: Review

References (94)

1. He W, Sengupta M, Velkoff VA et al. 65+in the United States: 2005. Washington, DC: US Census Bureau (online), Current Population Reports, 2005. Available at Accessed July 2, 2009.
2. Rowe JW, Kahn RL. Successful Aging. New York : Dell Publishing, 1998.
3. Kannel WB. Coronary heart disease risk factors in the elderly. Am J Geriatr Cardiol 2002 11 : 101 107.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: Findings from the Third National Health and Nutrition Examination Survey. JAMA 2002 287 : 356 359.
5. Chaves PHM, Kuller LH, O'Leary DH et al. Subclinical cardiovascular disease in older adults: Insights from the Cardiovascular Health Study. Am J Geriatr Cardiol 2004 13 : 137 151.
6. Bowler JV. Modern concept of vascular cognitive impairment. Br Med Bull 2007 83 : 291 305.
7. Sachdev P. Vascular cognitive disorder. Int J Geriatr Psychiatry 1999 14 : 402 403.
8. Black SE. Therapeutic issues in vascular dementia: Studies, designs and approaches. Can J Neurol Sci 2007 34 : S125 S130.
9. Leblanc GC, Meschia JF, Stuss DT et al. Genetics of vascular cognitive impairment: The opportunity and the challenges. Stroke 2006 37 : 248 255.
10. Langa KM, Foster NL, Larson EB. Mixed dementia: Emerging concepts and therapeutic implications. JAMA 2004 292 : 2901 2908.
11. White L, Small BJ, Petrovitch H et al. Recent clinical-pathologic research on the causes of dementia in later life: Update from the Honolulu-Asia Aging Study. J Geriatr Psychiatry Neurol 2005 18 : 224 227.
12. Neuropathology Group. Medical Research Council Cognitive Function and Aging Study (MRC CFAS). Pathologic correlates of late onset dementia in a multicentre, community-based population in England and Wales. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Lancet 2001 357 : 169 175.
13. Schneider JA, Arvanitakis Z, Bang W et al. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 2007 69 : 2197 2204.
14. Schneider JA, Aggarwal NT, Barnes L et al. The neuropathology of older persons with and without dementia from community versus clinic cohorts. J Alzheimers Dis 2009 18 : 691 701.
15. Sacco RL, Boden-Albala B, Abel G et al. Race-ethnic disparities in the impact of stroke risk factors: The Northern Manhattan Stroke Study. Stroke 2001 32 : 1725 1731.
16. Burke GL, Arnold AM, Bild DE et al. Factors associated with healthy aging: The Cardiovascular Health Study. J Am Geriatr Soc 2001 49 : 254 262.
17. Willcox BJ, He Q, Chen R et al. Midlife risk factors and healthy survival in men. JAMA 2006 296 : 2343 2350.
18. Birns J, Kalra L. Cognitive function and hypertension. J Hum Hypertens 2009 23 : 86 96.
19. Verghese J, Lipton RB, Hall CB et al. Low blood pressure and the risk of dementia in very old individuals. Neurology 2003 61 : 1667 1672.
20. Cacciatore F, Abete P. Mortality and blood pressure in elderly people with and without cognitive impairment. Gerontology 2005 51 : 53 61.
21. Waldstein SR, Giggey PP. Nonlinear relations of blood pressure to cognitive function: The Baltimore Longitudinal Study of Aging. Hypertension 2005 45 : 374 379.
22. Hayden KM, Zandi PP, Lyketsos CG et al. Vascular risk factors for incident Alzheimer disease and vascular dementia: The Cache County Study. Alzheimer Dis Assoc Disord 2006 20 : 93 100.
23. Romero JS, Beiser A, Seshadri S et al. Carotid artery atherosclerosis, MRI indices of brain ischemia, aging, and cognitive Impairment: The Framingham Study. Stroke 2009 40 : 1590 1596.
24. Cramer C, Haan MN, Galea S et al. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008 71 : 344 350.
25. Glynn RJ, Beckett LA, Hebert LE et al. Current and remote blood pressure and cognitive decline. JAMA 1999 281 : 438 445.
26. Anson O, Paran E. Hypertension and cognitive functioning among the elderly: An overview. Am Therapeut 2005 12 : 359 365.
27. Paran E, Anson O, Lowenthal DT. Cognitive function and antihypertensive treatment in the elderly: A 6-year follow-up study. Am J Ther 2010 March 3. [Epub ahead of print].
28. Kalmijn S, Feskens EJ, Launer LJ et al. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995 38 : 1096 1102.
29. Xu W, Qiu C, Gatz M et al. Mid- and late-life diabetes in relation to the risk of dementia: A population-based twin study. Diabetes 2009 58 : 71 77.
30. Launer LJ. Diabetes: Vascular or neurodegenerative: An epidemiologic perspective. Stroke 2009 40 : S53 S55.
31. Reitz C, Luchsinger JA, Mayeux R. Vascular disease and cognitive impairment. Expert Rev Neurother 2008 8 : 1171 1174.
32. Munch G, Schinzel R, Loske C et al. Alzheimer's disease-synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J Neural Transm 1998 105 : 439 461.
33. Haan MN, Shemanski L, Jagust WJ et al. The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons. JAMA 1999 282 : 40 46.
34. Wu JH, Haan MN, Liang J et al. Impact of antidiabetic medications on physical and cognitive functioning of older Mexican Americans with diabetes mellitus: A population-based cohort study. Ann Epidemiol 2003 13 : 369 376.
35. Schmidt R, Launer LJ, Nilsson LG et al. Magnetic resonance imaging of the brain in diabetes: The Cardiovascular Determinants of Dementia (CASCADE) Study. Diabetes 2004 53 : 687 692.
36. Hebert R, Lindsay J, Verreault R et al. Vascular dementia: Incidence and risk factors in the Canadian Study of Health and Aging. Stroke 2000 31 : 1487 1493.
37. Zhang JG, Yang JG, Lin ZX et al. Apolipoprotein E epsilon4 allele is a risk factor for late-onset Alzheimer's disease and vascular dementia in Han Chinese. Int J Geriatr Psychiatry 2001 16 : 438 439.
38. Poirier J. Apolipoprotein E and cholesterol metabolism in the pathogenesis and treatment of Alzheimer's disease. Trends Mol Med 2003 9 : 94 101.
39. Martins IJ, Hone E, Foster JK et al. Apolipoprotein E, cholesterol metabolism, diabetes, and the convergence of risk factors for Alzheimer's disease and cardiovascular disease. Mol Psychiatry 2006 11 : 721 736.
40. Peila R, Rodriquez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. Diabetes 2002 51 : 1256 1262.
41. Yaffe K, Weston AL, Blackwell T et al. The metabolic syndrome and development of cognitive impairment among older women. Arch Neurol 2009 66 : 324 328.
42. Stampfer MJ, Kang JH, Chen J et al. Effects of moderate alcohol consumption on cognitive function in women. N Engl J Med 2005 352 : 245 253.
43. Wright CB, Elkind MSV, Rundek T et al. Alcohol intake, carotid plaque, and cognition: The Northern Manhattan Study. Stroke 2006 37 : 1160 1164. (Pubitemid 43731855)
44. Coresh J, Selvin E, Stevens LA et al. Prevalence of chronic kidney disease in the United States. JAMA 2007 298 : 2038 2047. (Pubitemid 350074801)
45. Etgen T, Sander D, Chonchol M et al. Chronic kidney disease is associated with incident cognitive impairment in the elderly: The INVADE study. Nephrol Dial Transplant 2009 24 : 3144 3150.
46. Go AS, Chertow GM, Fan D et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004 351 : 1296 1305.
47. O'Hare AM, Bertenthal D, Covinsky KE et al. Mortality risk stratification in chronic kidney disease: One size for all ages? J Am Soc Nephrol 2006 17 : 846 854.
48. Kurella M, Chertow GM, Fried LF et al. Chronic kidney disease and cognitive impairment in the elderly: The Health, Aging, and Body Composition Study. J Am Soc Nephrol 2005 16 : 2127 2133.
49. Seliger S, Siscovick DS, Stehman-Breen CO et al. Moderate renal impairment and risk of dementia among older adults: The Cardiovascular Health Cognition Study. J Am Soc Nephrol 2004 15 : 1904 1911.
50. Fukunishi I, Kitaoka T, Shirai T et al. Psychiatric disorders among patients undergoing hemodialysis therapy. Nephron 2002 91 : 344 347.
51. Buchman AS, Tanne D, Boyle PA et al. Kidney function is associated with the rate of cognitive decline in the elderly. Neurology 2009 73 : 920 927.
52. Khatri MK, Wright CB, Nickolas TL et al. Chronic kidney disease is associated with white matter hyperintensity volume: The Northern Manhattan Study (NOMAS). Stroke 2007 38 : 3121 3126.
53. Khatri M, Nickolas T, Moon YP et al. CKD associates with cognitive decline. J Am Soc Nephrol 2009 20 : 2427 2432.
54. de Craen AJ, Gussekloo J, Vrijsen B et al. Meta-analysis of nonsteroidal antiinflammatory drug use and risk of dementia. Am J Epidemiol 2005 161 : 114 120.
55. Aisen PS, Schafer KA, Grundman M et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003 289 : 2819 2826.
56. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 2002 325 : 1202.
57. Aisen PS, Schneider LS, Sano M et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA 2008 300 : 1774 1783.
58. Ebbing M, Bleie Ø, Ueland PM et al. Mortality and cardiovascular events in patients treated with homocysteine-lowering B vitamins after coronary angiography: A randomized controlled trial. JAMA 2008 300 : 795 804.
59. Weaver JD, Huang MH, Albert M et al. Interleukin-6 and risk of cognitive decline: MacArthur Studies of Successful Aging. Neurology 2002 59 : 371 378.
60. Schmidt R, Schmidt H, Curb JD et al. Early inflammation and dementia: A 25-year follow-up of the Honolulu-Asia Aging Study. Ann Neurol 2002 52 : 168 174.
61. Yaffe K, Kanaya A, Lindquist K et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004 292 : 2237 2242.
62. Wright CB, Paik MC, Brown TR et al. Total homocysteine is associated with white matter hyperintensity volume: The Northern Manhattan Study. Stroke 2005 36 : 1207 1211.
63. Lynch MA. Age-related impairment in long-term potentiation in hippocampus: A role for the cytokine, interleukin-1 beta? Prog Neurobiol 1998 56 : 571 589.
64. Tsia SJ, Hong CJ, Liu ME et al. Interleukin-1 beta (C-511T) genetic polymorphism is associated with cognitive performance in elderly males without dementia. Neurbiol Aging 2008 November 13. [Epub ahead of print].
65. Bots ML, van Swieten JC, Breteler MM et al. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study. Lancet 1993 341 : 1232 1237.
66. Meyer JS, Kawamura J, Terayama Y. White matter lesions in the elderly. J Neurol Sci 1992 110 : 1 7.
67. de Leeuw FE, de Groot JC, Breteler MMB. White matter changes: Frequency and risk factors. In : Pantoni L, Inzitari D, Wallin A, editors. The Matter of White Matter: Clinical and Pathophysiological Aspects of White Matter Disease Related to Cognitive Decline and Vascular Dementia. Academic Pharmaceutical Productions, Utrecht, the Netherlands : 2001, pp 19 33.
68. Markus HS, Hunt B, Palmer K et al. Markers of endothelial and hemostatic activation and progression of cerebral white matter hyperintensities: Longitudinal results of the Austrian Stroke Prevention Study. Stroke 2005 36 : 1410 1414.
69. Moody DM, Thore CR, Anstrom JA et al. Quantification of afferent vessels shows reduced brain vascular density in subjects with leukoaraiosis. Radiology 2004 233 : 883 890.
70. Pico F, Dufouil C, Levy C et al. Longitudinal study of carotid atherosclerosis and white matter hyperintensities: The EVA-MRI cohort. Cerebrovasc Dis 2002 14 : 109 115.
71. Fazekas F, Kleinert R, Offenbacher H et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993 43 : 1683 1689.
72. Jeerakathil T, Wolf PA, Beiser A et al. Stroke risk profile predicts white matter hyperintensity volume: The Framingham Study. Stroke 2004 35 : 1857 1861. (Pubitemid 38971865)
73. Gouw AA, van der Flier WM, Fazekas F et al. Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: The Leukoaraiosis and Disability Study. Stroke 2008 39 : 1414 1420.
74. Taylor WD, Steffens DC, MacFall JR et al. White matter hyperintensity progression and late-life depression outcomes. Arch Gen Psychiatry 2003 60 : 1090 1096.
75. Whitman GT. A prospective study of cerebral white matter abnormalities in older people with gait dysfunction. Neurology 2001 57 : 990 994.
76. Ylikoski A, Erkinjuntti T, Raininko R et al. White matter hyperintensities on MRI in the neurologically nondiseased elderly: Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke 1995 26 : 1171 1177.
77. Elmer PJ, Obarzanek E, Vollmer WM et al. Effects of comprehensive lifestyle modification on diet, weight, physical fitness, and blood pressure control: 18-month results of a randomized trial. Ann Intern Med 2006 144 : 485 495.
78. Korf ES, White LR, Scheltens P et al. Midlife blood pressure and the risk of hippocampal atrophy: The Honolulu Asia Aging Study. Hypertension 2004 44 : 29 34.
79. Raz N, Rodrigue KM, Acker JD. Hypertension and the brain: Vulnerability of the prefrontal regions and executive functions. Behav Neurosci 2003 117 : 1169 1180.
80. Longstreth WT Jr., Bernick C, Manolio TA et al. Lacunar infarcts defined by magnetic resonance imaging of 3660 elderly people: The Cardiovascular Health Study. Arch Neurol 1998 55 : 1217 1225.
81. Shinkawa A, Ueda K, Kiyohara Y et al. Silent cerebral infarction in a community-based autopsy series in Japan. The Hisayama Study. Stroke 1995 26 : 380 385.
82. Vermeer SE, Koudstaal PJ, Oudkerk M et al. Prevalence and risk factors of silent brain infarcts in the population-based Rotterdam Scan Study. Stroke 2002 33 : 21 25.
83. Schneider JA, Wilson RS, Bienias JL et al. Cerebral infarcts and the likelihood of dementia from Alzheimer's disease pathology. Neurology 2004 62 : 1148 1152.
84. Snowdon DA, Greiner LH, Mortimer JA et al. Brain infarction and the clinical expression of AD: The Nun Study. JAMA 1997 277 : 813 817.
85. Vermeer SE, Prins ND, den Heijer T et al. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med 2003 348 : 1215 1222.
86. Bernick C, Kuller L, Dulberg C et al. Silent MRI infarcts and the risk of future stroke: The Cardiovascular Health Study. Neurology 2001 57 : 1222 1229.
87. Maeshima S, Moriwaki H, Ozaki F et al. Silent cerebral infarction and cognitive function in middle-aged neurologically healthy subjects. Acta Neurol Scand 2002 105 : 179 184.
88. Prabhakaran S, Wright CB, Yoshita M et al. Prevalence and determinants of subclinical brain infarction: The Northern Manhattan Study. Neurology 2008 70 : 425 430.
89. Wright CB, Festa JF, Paik MC et al. White matter hyperintensities and subclinical infarction: Associations with psychomotor speed and cognitive flexibility. Stroke 2008 39 : 800 805.
90. Au R, Massaro JM, Wolf PA et al. Association of white matter hyperintensity volume with decreased cognitive functioning: The Framingham Heart Study. Arch Neurol 2006 63 : 246 250.
91. Administration on Aging (AoA). A Profile of Older Americans: 2003. Administration on Aging. Washington, DC : US Department of Health and Human Services, 2003.
92. Richards M, Deary IJ. A life course approach to cognitive reserve: A model for cognitive aging and development? Ann Neurol 2005 58 : 617 622.
93. Knopman D, Boland LL, Mosley T et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. Neurology 2001 56 : 42 48.
94. Saczynski JS, Jonsdottir MK, Garcia ME et al. Cognitive impairment: An increasingly important complication of type 2 diabetes: The age, gene\environment susceptibility - Reykjavik Study. Am J Epidemiol 2008 168 : 1132 1139.